The second China biomedical innovation and cooperation conference, sponsored by Wanyi medicine, CO organized by Zhejiang Pharmaceutical Industry Association and supported by Baihua Association, Huoshi creation, new drug founder club, Yaodu, British Chinese trade association and other institutions, will be held in Hangzhou with 600 + experts in pharmaceutical R & D / registration and application. The conference has 4 sub forums, 50 + theme reports, 6 interactive round table discussions, focusing on antibody drug development, drug registration and approval, tumor immunotherapy, artificial intelligence driven new drug development, ADC drug development, Nash new drug progress, personalized cancer vaccine development and other topics.
Meeting time: June 19-20, 2020 (Friday, Saturday)
Conference Hotel: Yilin Hotel Hangzhou and Hilton
Address: No.600 Jinsha Avenue, economic and Technological Development Zone, Hangzhou, Zhejiang, China
Hongbo pharmaceutical has an appointment with you in June
Sub forum 3: innovative drug research and development ideas
Title of speech
New drug R & D strategy of cro service model
Dr. Cai Zhenwei
Senior vice president, chemistry
Doctor, Rutgers University, USA
Senior vice president, chemical department, Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. (2010 present)
Major inventors of the anti-tumor innovative drugs brivanib (clinical phase III) and tibsovo (FDA approved in 2018).
More than 30 global invention patents (won Thomas Edison patent invention award in 2011)
Hongbo pharmaceutical booth No.: A013
Hongbo pharmaceutical is a rapidly developing new drug R & D service and API manufacturer. Since its establishment in December 2007, the company has been actively cooperating with customers and business partners to become a leading enterprise in the research, production and sales of new drug creation services and API process innovation with the driving force of scientific and technological innovation and the goal of creating a distinctive "intelligent" innovation enterprise.
Hongbo pharmaceutical headquarter is located in the east of Zhangjiang hi tech Industrial Park, Pudong New Area, Shanghai, with nearly 120000 square meters of office area, laboratory and advanced equipment. At present, it has a variety of experimental and detection equipment, such as NMR, SFC, HPLC, chiral-hplc, LC-MS, LC-MS / MS (API 4000), GC-MS, positive / reverse phase preparative chromatography, microwave synthesizer, etc. As a high-tech enterprise, the company has so far applied for 44 invention patents (including 5 PCTs), 22 authorized patents and 44 applied patents.
Hongbo Zhiyuan (Kaiyuan) pharmaceutical industry, located in Kaiyuan city, Liaoning Province, is a production base with an area of 150000 square meters. It has workshops and inspection systems that meet the current GMP standards. It is mainly engaged in the R & D, production and sales of high-end chemical APIs and intermediates. Its existing products include tegrilo, paramiway, etc., and has obtained the EU cos Certificate and a number of international high-end certification, at the same time, with the United States Pfizer, Abbott, Switzerland Novartis, France Sanofi and other well-known foreign enterprises long-term cooperation, with considerable development potential.
Dr. Chen Ping, the founder of the company, and Dr. Cai Zhenwei, the senior vice president of pharmaceutical chemistry, are senior experts in pharmaceutical chemistry. They won the Thomas Edison new drug invention patent award in 2008 and 2011 respectively for their outstanding contributions to a class of new anti-cancer drugs.
For more information, please call + 86-21-50720058 or visit www.pharmaresources.cn 。
Business Consulting: firstname.lastname@example.org
recruitment information: email@example.com
Sales services: firstname.lastname@example.org